Neurologix Licenses Promising New Gene for Treatment of CNS Disorders

Neurologix which through its subsidiary Neurologix Research, is engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system (CNS) primarily utilizing gene therapies, announced that it has licensed the humanin gene from Keio University in Tokyo Japan as part of a strategic move to broaden its product portfolio. The license agreement provides Neurologix with exclusive worldwide rights (excluding Japan) to develop and commercialize therapeutics to treat brain and other CNS disorders (excluding Amyotrophic Lateral Sclerosis) using the humanin gene.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=531452XSL_NEWSML_TO_NEWSML_WEB.xml)